CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment

ConclusionCYP2C19*3 polymorphism could be an important predictive factor of HPR and ischemic cardiovascular adverse events after clopidogrel treatment.
Source: Journal of Clinical Laboratory Analysis - Category: Laboratory Medicine Authors: Tags: RESEARCH ARTICLE Source Type: research